Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $6.0 million
Deal Type : Public Offering
Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
Details : The net proceeds will be used to advance the Company’s pre-clinical studies, including SIL-204, encapsulated in biodegradable PLGA MP, for direct release and injection into KRAS mutated solid tumors.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
September 11, 2025
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $6.0 million
Deal Type : Public Offering
Silexion Reports 97% Cancer Cell Growth Inhibition, Including New KRAS Mutation
Details : SIL204 is a KRAS inhibitor siRNA candidate, which is being evaluated for the treatment of pancreatic cancer.
Product Name : SIL204
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 31, 2025
Silexion's SIL204 Shows Strong Preclinical Efficacy in Multiple Cancer Types
Details : Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 29, 2025
Details : SIL204 is designed to inhibit the KRAS-driven oncogenic process, currently being investigated for patients with pancreatic cancers.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 29, 2025
Lead Product(s) : SIL204
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Silexion Wraps Up Preclinical Studies of SIL204 for Lung and Colorectal Cancer
Details : Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 21, 2025
Lead Product(s) : SIL204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Silexion Partners with Catalent on Advanced siRNA Development
Details : The collaboration aims to advnace the clinical development of Silexion's SIL-204, which is a next-generation siRNA candidate. It is being evaluated for KRAS-mutated cancers.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 23, 2025
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Silexion Reports Positive SIL204 Data in Pancreatic Cancer Models
Details : SIL204 is an innovative RNA interference (RNAi) therapies, which is currently being evaluated for the treatment of solid tumors driven by KRAS mutations.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Silexion Completes Study on SIL-204 in Orthotopic Pancreatic Cancer Models
Details : SIL 204 is an anti KRAS G12D/V short-interfering RNA, which is being evaluated for KRAS G12D/V-mutated pancreatic neoplasms.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Silexion Reports SIL-204 Reduces Pancreatic Tumor Growth
Details : SIL-204 is a next-generation siRNA therapeutic candidate administered subcutaneously inhibited tumor growth in KRAS G12D/V-mutated pancreatic neoplasms mouse models.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $5.0 million
Deal Type : Public Offering
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Details : The net proceeds from the offering will advance the Company’s pre-clinical studies of SIL-204, which is being evaluated for KRAS G12D/V-mutated Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
January 15, 2025
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $5.0 million
Deal Type : Public Offering